Publicacions en col·laboració amb investigadors/es de Complejo Hospitalario Universitario de Albacete (24)

2021

  1. MZ1 co-operates with trastuzumab in HER2 positive breast cancer

    Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1

2020

  1. Checkpoint kinase 1 pharmacological inhibition synergizes with dna-damaging agents and overcomes platinum resistance in basal-like breast cancer

    International Journal of Molecular Sciences, Vol. 21, Núm. 23, pp. 1-14

  2. Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer

    Cancer Letters, Vol. 491, pp. 50-59

  3. Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer

    Journal of Cellular and Molecular Medicine, Vol. 24, Núm. 5, pp. 3117-3127

2019

  1. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer

    Journal of Experimental and Clinical Cancer Research, Vol. 38, Núm. 1

  2. Screening and preliminary biochemical and biological studies of [RuCl(p-cymene)(N, N-bis(diphenylphosphino)-isopropylamine)][BF4] in Breast Cancer Models

    ACS Omega, Vol. 4, Núm. 8, pp. 13005-13014

2017

  1. Regulation of the prometastatic neuregulin–MMP13 axis by SRC family kinases: therapeutic implications

    Molecular Oncology, Vol. 11, Núm. 12, pp. 1788-1805

  2. Synthetic lethality interaction between aurora kinases and CHEK1 inhibitors in ovarian cancer

    Molecular Cancer Therapeutics, Vol. 16, Núm. 11, pp. 2552-2562

  3. Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors

    Oncotarget, Vol. 8, Núm. 12, pp. 19478-19490

2016

  1. Breast cancer dissemination promoted by a neuregulin-collagenase 3 signalling node

    Oncogene, Vol. 35, Núm. 21, pp. 2756-2765

  2. In silico analysis guides selection of BET Inhibitors for triple-negative breast cancer treatment

    Molecular Cancer Therapeutics, Vol. 15, Núm. 8, pp. 1823-1833

  3. Neuregulin expression in solid tumors: Prognostic value and predictive role to anti-HER3 therapies

    Oncotarget, Vol. 7, Núm. 29, pp. 45042-45051

  4. Targeting the EGF/HER ligand-receptor system in cancer

    Current Pharmaceutical Design, Vol. 22, Núm. 39, pp. 5887-5898

2015

  1. Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer

    Oncotarget, Vol. 6, Núm. 29, pp. 27923-27937

  2. Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2

    Oncotarget, Vol. 6, Núm. 32, pp. 32856-32867

  3. Phospho-kinase profile of colorectal tumors guides in the selection of multi-kinase inhibitors

    Oncotarget, Vol. 6, Núm. 31, pp. 31272-31283

2014

  1. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer

    Oncogene, Vol. 33, Núm. 2, pp. 148-156

  2. Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling

    BMC Cancer, Vol. 14, Núm. 1

2012

  1. Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: Therapeutic implications

    Molecular Cancer Therapeutics, Vol. 11, Núm. 6, pp. 1342-1352

2011

  1. Inhibition of Src family kinases and receptor tyrosine kinases by dasatinib: Possible combinations in solid tumors

    Clinical Cancer Research, Vol. 17, Núm. 17, pp. 5546-5552